GSA Capital Partners LLP Has $96,000 Stake in CorMedix Inc. (NASDAQ:CRMD)

GSA Capital Partners LLP reduced its position in CorMedix Inc. (NASDAQ:CRMD) by 71.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,825 shares of the company’s stock after selling 30,294 shares during the quarter. GSA Capital Partners LLP’s holdings in CorMedix were worth $96,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its holdings in CorMedix by 21.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,635 shares of the company’s stock valued at $63,000 after buying an additional 2,562 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of CorMedix by 13.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,190 shares of the company’s stock worth $100,000 after acquiring an additional 2,700 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of CorMedix by 10.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 52,184 shares of the company’s stock valued at $422,000 after purchasing an additional 4,935 shares during the period. Sigma Planning Corp boosted its position in shares of CorMedix by 23.8% during the 3rd quarter. Sigma Planning Corp now owns 39,947 shares of the company’s stock valued at $323,000 after purchasing an additional 7,679 shares in the last quarter. Finally, Principal Financial Group Inc. acquired a new position in shares of CorMedix during the second quarter valued at about $44,000. 34.18% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on CRMD shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $9.00 price target on shares of CorMedix in a research note on Thursday, August 15th. Rodman & Renshaw initiated coverage on CorMedix in a research report on Monday, August 26th. They set a “buy” rating and a $13.00 target price on the stock. Truist Financial lifted their price target on shares of CorMedix from $12.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. StockNews.com upgraded shares of CorMedix to a “sell” rating in a report on Friday, November 8th. Finally, Needham & Company LLC lifted their price objective on shares of CorMedix from $10.00 to $18.00 and gave the company a “buy” rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $15.20.

CorMedix Trading Down 0.1 %

NASDAQ CRMD opened at $9.95 on Tuesday. The firm has a market capitalization of $603.77 million, a P/E ratio of -12.30 and a beta of 1.58. The business has a fifty day simple moving average of $9.93 and a 200 day simple moving average of $6.71. CorMedix Inc. has a 12 month low of $2.89 and a 12 month high of $13.85.

CorMedix (NASDAQ:CRMD) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. The firm had revenue of $11.46 million during the quarter, compared to the consensus estimate of $11.00 million. During the same period in the previous year, the company posted ($0.17) earnings per share. As a group, sell-side analysts predict that CorMedix Inc. will post -0.46 EPS for the current fiscal year.

Insider Buying and Selling at CorMedix

In other news, EVP Elizabeth Hurlburt sold 140,027 shares of the stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $11.18, for a total transaction of $1,565,501.86. Following the completion of the transaction, the executive vice president now directly owns 45,397 shares of the company’s stock, valued at $507,538.46. This represents a 75.52 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 5.20% of the company’s stock.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.